These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 31868033)

  • 1. Patient-reported outcomes in elderly patients with type 2 diabetes mellitus treated with dual oral therapy: a multicenter, observational study from Italy.
    Lapolla A; Genovese S; Giorgino F; Disoteo O; Sartore G; Bartezaghi M; Del Prato S
    Curr Med Res Opin; 2020 Apr; 36(4):555-562. PubMed ID: 31868033
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment patterns and satisfaction in patients with type 2 diabetes newly initiating oral monotherapy with antidiabetic drugs in Japan: results from the prospective Real-world Observational Study on Patient Outcomes in Diabetes (RESPOND).
    Tajima A; Tobe K; Eiki JI; Origasa H; Watada H; Shimomura I; Tokita S; Kadowaki T
    BMJ Open Diabetes Res Care; 2022 Dec; 10(6):. PubMed ID: 36585033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia.
    Ushakova O; Sokolovskaya V; Morozova A; Valeeva F; Zanozina O; Sazonova O; Zhadanova E; Starceva M; Kazakova E; Saifullina M; Shapiro I; Tarasov A; Al-Tayar B; Starkova N
    Clin Ther; 2007 Nov; 29(11):2374-84. PubMed ID: 18158078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of oral antidiabetic agents with basal insulin versus premixed insulin alone in randomized elderly patients with type 2 diabetes mellitus.
    Janka HU; Plewe G; Busch K
    J Am Geriatr Soc; 2007 Feb; 55(2):182-8. PubMed ID: 17302653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness and safety of vildagliptin and vildagliptin add-on to metformin in real-world settings in Egypt - results from the GUARD study.
    Shelbaya S; Rakha S
    Curr Med Res Opin; 2017 May; 33(5):797-801. PubMed ID: 28303721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fixed-dose combination antidiabetic therapy: real-world factors associated with prescribing choices and relationship with patient satisfaction and compliance.
    Benford M; Milligan G; Pike J; Anderson P; Piercy J; Fermer S
    Adv Ther; 2012 Jan; 29(1):26-40. PubMed ID: 22246944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of generic exenatide injection in Chinese patients with type 2 diabetes: a multicenter, randomized, controlled, non-inferiority trial.
    Yang J; Xiao W; Guo L; Li Q; Zhong L; Yang J; Yang J; Gao Y; Tian Q; Hong T
    Acta Diabetol; 2020 Aug; 57(8):991-1000. PubMed ID: 32206903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences in glycemic control across world regions: a post-hoc analysis in patients with type 2 diabetes mellitus on dual antidiabetes drug therapy.
    Brath H; Paldánius PM; Bader G; Kolaczynski WM; Nilsson PM
    Nutr Diabetes; 2016 Jul; 6(7):e217. PubMed ID: 27376699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-life safety and efficacy of vildagliptin as add-on to metformin in patients with type 2 diabetes in Turkey--GALATA study.
    Ayvaz G; Keskin L; Akin F; Dokmetas HS; Tasan E; Ar IB; Uren E;
    Curr Med Res Opin; 2015 Apr; 31(4):623-32. PubMed ID: 25697921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initial combination therapy with vildagliptin plus metformin in drug-naïve patients with T2DM: a 24-week real-life study from Asia.
    Chawla M; Kim TH; Mirasol RC; Faruque P; Cooke K; Hours-Zesiger P; Shete A
    Curr Med Res Opin; 2018 Sep; 34(9):1605-1611. PubMed ID: 29764225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of insulin glulisine as mono- or add-on therapy in patients with type 2 diabetes mellitus.
    Kawamori R; Iwamoto Y; Kadowaki T; Iwasaki M; Kim SW; Woo JT; Baik SH; Yoon KH
    Diabetes Obes Metab; 2009 Sep; 11(9):900-9. PubMed ID: 19614946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of baseline characteristics, glycemic control and oral antidiabetic treatment in Asian patients with diabetes: The Registry for Assessing OAD Usage in Diabetes Management (REASON) Asia study.
    Vichayanrat A; Matawaran BJ; Wibudi A; Ferdous HS; Aamir AH; Aggarwal SK; Bajpai S
    J Diabetes; 2013 Sep; 5(3):309-18. PubMed ID: 23462227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of combination therapy with vildagliptin and metformin versus metformin uptitration in Chinese patients with type 2 diabetes inadequately controlled with metformin monotherapy: a randomized, open-label, prospective study (VISION).
    Ji LN; Pan CY; Lu JM; Li H; Zhu DL; Li Q; Li QF; Peng YD; Tian HM; Yao C; Zhao ZG; Wang L; Wang BH;
    Diabetes Obes Metab; 2016 Aug; 18(8):775-82. PubMed ID: 27406394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Efficacy and safety of vildagliptin as a second-line therapy vs other oral antidiabetic agents in patients with type 2 diabetes: Czech results within the worldwide prospective cohort EDGE study].
    Haluzík M; Veselá V; Gerle J; Brada M; Dohnalová L; Edelsberger T; Houdová J
    Vnitr Lek; 2013 Dec; 59(12):1049-56. PubMed ID: 24350936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of hypoglycemia among a sample of sulfonylurea-treated patients with Type 2 diabetes mellitus in Argentina: The real-life effectiveness and care patterns of diabetes management (RECAP-DM) study.
    Gonzalez C; Monti C; Pinzon A; Monsanto H; Ejzykowicz F;
    Endocrinol Diabetes Nutr (Engl Ed); 2018 Dec; 65(10):592-602. PubMed ID: 30076124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and tolerability of second-line treatment with vildagliptin versus other oral drugs for type 2 diabetes in a real-world setting in the Middle East: results from the EDGE study.
    Saab C; Al-Saber FA; Haddad J; Jallo MK; Steitieh H; Bader G; Ibrahim M
    Vasc Health Risk Manag; 2015; 11():149-55. PubMed ID: 25750538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic review and meta-analysis of randomized clinical trials comparing efficacy and safety outcomes of insulin glargine with NPH insulin, premixed insulin preparations or with insulin detemir in type 2 diabetes mellitus.
    Rys P; Wojciechowski P; Rogoz-Sitek A; Niesyczyński G; Lis J; Syta A; Malecki MT
    Acta Diabetol; 2015 Aug; 52(4):649-62. PubMed ID: 25585592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of initiating biphasic human insulin 30 therapy in type 2 diabetes patients after failure of oral antidiabetes drugs.
    Gu Y; Hou X; Zhang L; Pan J; Cai Q; Bao Y; Jia W
    Diabetes Technol Ther; 2012 Mar; 14(3):244-50. PubMed ID: 22047050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of metformin-based oral antidiabetic drugs is not inferior to insulin glargine in newly diagnosed type 2 diabetic patients with severe hyperglycemia after short-term intensive insulin therapy.
    Cheng Q; Yang S; Zhao C; Wang Z; Feng Z; Li R; Ye P; Zhang S; Deng H; Zhou B; Long J; Gong L; Qing H; Luo C; Li Q
    J Diabetes; 2015 Mar; 7(2):182-91. PubMed ID: 24823280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liraglutide is effective and well tolerated in combination with an oral antidiabetic drug in Japanese patients with type 2 diabetes: A randomized, 52-week, open-label, parallel-group trial.
    Kaku K; Kiyosue A; Ono Y; Shiraiwa T; Kaneko S; Nishijima K; Bosch-Traberg H; Seino Y
    J Diabetes Investig; 2016 Jan; 7(1):76-84. PubMed ID: 26816604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.